Sachdev Shivani, Creemer Brendan A, Gardella Thomas J, Cheloha Ross W
bioRxiv. 2023 Oct 13:2023.10.10.561766. doi: 10.1101/2023.10.10.561766.
Ligand-induced activation of G protein-coupled receptors (GPCRs) can initiate signaling through multiple distinct pathways with differing biological and physiological outcomes. There is intense interest in understanding how variation in GPCR ligand structure can be used to promote pathway selective signaling ("biased agonism") with the goal of promoting desirable responses and avoiding deleterious side effects. Here we present a new approach in which a conventional peptide ligand for the type 1 parathyroid hormone receptor (PTHR1) is converted from an agonist which induces signaling through all relevant pathways to a compound that is highly selective for a single pathway. This is achieved not through variation in the core structure of the agonist, but rather by linking it to a nanobody tethering agent that binds with high affinity to a separate site on the receptor not involved in signal transduction. The resulting conjugate represents the most biased agonist of PTHR1 reported to date. This approach holds promise for facile generation of pathway selective ligands for other GPCRs.
配体诱导的G蛋白偶联受体(GPCRs)激活可通过多种不同途径启动信号传导,产生不同的生物学和生理学结果。人们对理解GPCR配体结构的变化如何用于促进途径选择性信号传导(“偏向激动作用”)有着浓厚兴趣,目的是促进理想反应并避免有害副作用。在此,我们提出一种新方法,其中用于1型甲状旁腺激素受体(PTHR1)的传统肽配体从通过所有相关途径诱导信号传导的激动剂转变为对单一途径具有高度选择性的化合物。这不是通过激动剂核心结构的变化实现的,而是通过将其与纳米抗体 tethering 剂连接来实现,该纳米抗体 tethering 剂与受体上不参与信号转导的另一个位点高亲和力结合。所得共轭物是迄今为止报道的PTHR1最具偏向性的激动剂。这种方法有望为其他GPCR轻松生成途径选择性配体。